Second-line treatment of advanced gastric cancer: Where do we stand?

Amit Mahipal, Minsig Choi, Richard Kim

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


Gastric cancer is a leading cause of cancer death and is associated with poor prognosis. The treatment of advanced gastric cancer is changing with the development of novel agents. Until recently, no standard treatment was available for patients with advanced gastric cancer in the second-line setting. Single-agent chemotherapy with docetaxel or irinotecan has been shown to improve survival and quality of life in patients whose disease has progressed while on prior chemotherapy. Combination chemotherapy is associated with a modest benefit at the expense of increased toxicity. Recently, ramucirumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF) receptor-2, has been approved for the treatment of refractory advanced gastric cancer as a single agent or in combination with paclitaxel. Apatinib, a small molecule tyrosine kinase inhibitor targeting VEGF, has demonstrated activity in Asian populations whose disease has progressed on 2 lines of therapy. However, much work is still needed, including the development of biomarkers that could predict response to therapy.

Original languageEnglish (US)
Pages (from-to)1281-1292
Number of pages12
JournalJNCCN Journal of the National Comprehensive Cancer Network
Issue number10
StatePublished - Oct 1 2015

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Second-line treatment of advanced gastric cancer: Where do we stand?'. Together they form a unique fingerprint.

Cite this